MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

CTHRC1

Search medical newsFind research, conditions and clinical updates
  • Home
  • CTHRC1
A Stromal CTHRC1 Biomarker Framework May Identify Colorectal Cancers With Poor Prognosis and Limited Immunotherapy Benefit
Posted inGastroenterology news Oncology

A Stromal CTHRC1 Biomarker Framework May Identify Colorectal Cancers With Poor Prognosis and Limited Immunotherapy Benefit

Posted by By MedXY 05/10/2026
A large multiomic colorectal cancer study identifies CTHRC1-positive fibroblasts as a stromal biomarker linked to TGF-beta activity, adverse outcomes, and reduced checkpoint inhibitor benefit across both MSI and MSS disease.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Optimizing Outcomes in Donation After Circulatory Death Liver Transplantation: A Comparative Evaluation of Machine Preservation Techniques
  • Influence of Cardiometabolic Status on Cardiovascular Effects of Oral Menopausal Hormone Therapy
  • Decoding HBV Infection Heterogeneity Using B-BEST: Insights from Single-Cell Viral-Host Transcriptomics
  • Differences in Epilepsy Etiology, Type, Syndrome, and Severity Between Māori and Non-Māori-Non-Pasifika Children With Epilepsy in New Zealand
  • Unraveling the Heterogeneity of Adult-Onset Type 1 Diabetes: Clinical and Metabolic Subtypes Reveal New Insight for Precision Care
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top